Fluvastatin in the therapy of acute coronary syndrome

Not Applicable

Completed

• Conditions: Acute coronary syndrome (ACS); Circulatory System; Coronary diseases

• Registration Number: ISRCTN81331696
• Lead Sponsor: ovartis Pharma CR s.r.o.

Brief Summary

1. 2005 results in http://www.ncbi.nlm.nih.gov/pubmed/15790413 2. 2010 results in http://www.ncbi.nlm.nih.gov/pubmed/20500832

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2004-01-01
• Study Start: 2005-03-22
• Last Update Posted: 3 February 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

Eligible patients with ST elevation ACS must have resting chest pain less than 12 hours before admission and either >1 mm ST-segment elevation in 2 or more continuous leads or new left bundle branch block on electrocardiogram (ECG). Those with non-ST elevation ACS must have resting chest pain during the previous 48 hours and either >1 mm ST segment depression or negative T waves in 2 or more continuous leads.

Exclusion Criteria

Does not match inclusion criteria

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Influence of fluvastatin therapy on levels of inflammatory markers (CRP and interleukin-6) and on pregnancy associated plasma protein A (PAPP-A)

Secondary Outcome Measures

Name	Time	Method
A combined secondary endpoint is 30-day and one-year occurrence of death, nonfatal myocardial infarction, recurrent symptomatic ischemia, urgent revascularization, and cardiac arrest.